Allos Looks To ENRICH Trial To Secure Excelar Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee says product requires confirmatory data for approval in brain metastases related to breast cancer. Open-label study began in February.